Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 07, 2025 18:05 ET | Source: Bragar Eagel & Squire

ALTO ALERT: Bragar Eagel & Squire, P.C. is Investigating Alto Neuroscience, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

Alto allegedly overstated ALTO-100’s effectiveness and prospects; trial failure revealed weak results, causing shares to drop nearly 70%.
September 22, 2025 10:02 ET | Source: Grabar Law Office

Important Notice to Long-Term Shareholders of Alto Neuroscience, Inc. (NYSE: ANRO); Brainstorm Cell Therapeutics Inc. (OTC: BCLI); Flywire Corporation (NASDAQ: FLYW); and Ibotta, Inc. (NYSE: IBTA): Grabar Law Office is Investigating Claims on Your Behalf

PHILADELPHIA, Sept. 22, 2025 (GLOBE NEWSWIRE) -- Alto Neuroscience, Inc. (NYSE: ANRO): Grabar Law Office is investigating claims on behalf of shareholders of Alto Neuroscience, Inc. (NYSE: ANRO)....
September 19, 2025 09:50 ET | Source: The Rosen Law Firm PA

ANRO DEADLINE TODAY: ROSEN, A HIGHLY RECOGNIZED LAW FIRM, Encourages Alto Neuroscience, Inc. Investors to Secure Counsel Before Important September 19 Deadline in Securities Class Action - ANRO

NEW YORK, Sept. 19, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Alto Neuroscience, Inc. (NYSE: ANRO): (i) pursuant and/or...
September 19, 2025 07:23 ET | Source: Bragar Eagel & Squire

ANRO FINAL DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors in Alto Neuroscience, Inc. (ANRO) of the September 19th Deadline

Allegedly, Alto misled investors on ALTO-100’s effectiveness for MDD. After Phase 2b trial failure on Oct 22, 2024, shares fell nearly 70%.
September 17, 2025 23:40 ET | Source: Faruqi & Faruqi LLP

DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Alto Neuroscience

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Alto To Contact Him Directly To Discuss Their Options If you purchased or...
September 17, 2025 17:46 ET | Source: Bragar Eagel & Squire

ANRO DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors in Alto Neuroscience, Inc. (ANRO) of the September 19th Deadline

Alto allegedly overstated ALTO-100’s prospects in IPO filings; after Phase 2b trial failed, stock plunged nearly 70% on Oct. 23, 2024.
September 15, 2025 07:43 ET | Source: Bragar Eagel & Squire

ALTO NEUROSCIENCE DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Alto Neuroscience, Inc. (ANRO) and Encourages Investors to Contact the Firm

Alto allegedly overstated ALTO-100’s prospects; after trial failure revealed in Oct 2024, stock fell nearly 70% to $4.36 per share.
September 12, 2025 12:41 ET | Source: The Rosen Law Firm PA

ANRO DEADLINE NOTICE: ROSEN, A LEADING LAW FIRM, Encourages Alto Neuroscience, Inc. Investors to Secure Counsel Before Important September 19 Deadline in Securities Class Action - ANRO

NEW YORK, Sept. 12, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Alto Neuroscience, Inc. (NYSE: ANRO): (i) pursuant and/or...
September 11, 2025 19:18 ET | Source: Faruqi & Faruqi LLP

Faruqi & Faruqi Reminds Alto Neuroscience Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of September 19, 2025 - ANRO

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Alto To Contact Him Directly To Discuss Their Options If you purchased or...
September 11, 2025 07:54 ET | Source: Bragar Eagel & Squire

ALTO NEUROSCIENCE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Alto Neuroscience, Inc. (ANRO) and Encourages Investors to Contact the Firm

The complaint alleges Alto misled investors about ALTO-100’s effectiveness and prospects, overstating its value until failed trial results sank the stock.